AzTrials
AzTrials

Obstructive Sleep ApneaHBO-POSANCT07809061

Hypercapnic Burden in Adults With Obesity Undergoing Diagnostic Polysomnography for Suspected Obstructive Sleep Apnea

A study testing Sleep Inertia Questionnaire (SIQ) in people with Obstructive Sleep Apnea and Obesity (BMI>30), run by Hospices Civils de Lyon at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Obesity-related sleep hypoventilation represents a continuum ranging from isolated nocturnal hypoventilation to obesity hypoventilation syndrome. Current diagnostic criteria rely mainly on dichotomous thresholds and may not adequately reflect cumulative nocturnal carbon dioxide exposure. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Sleep Inertia Questionnaire (SIQ)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 siteFrance
Study dates
1 Nov 2026to 3 Nov 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years.
  • Body mass index (BMI) ≥30 kg/m².
  • Referred to the Sleep Medicine Center for routine diagnostic polysomnography because of suspected obstructive sleep apnea.
  • Affiliated with a French health insurance scheme.
  • Received information about the study and did not object to the use of their data.
  • Able to understand the study information and complete study questionnaires.

Who cannot join

  • Legal incapacity or inability to provide non-opposition to participation.
  • Previous treatment with continuous positive airway pressure (CPAP) or non-invasive ventilation.
  • Participation in another interventional clinical study that could interfere with the present study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Pierre TANKERE, Dr contact

0472071929

Pierre.tankere01@chu-lyon.fr

Laure PETER DEREX, Pr contact

0472071929

Laure.peter-derex@chu-lyon.fr

France1 site
  • Croix-Rousse Hospital, Hospices Civils de Lyon

    Lyon, 69004

    Pierre TANKERE, Dr, 0472071929, Pierre.tankere01@chu-lyon.fr

    Virginie INFANTI, Dr

Other trials in France

About this study

Official title: Hypercapnic Burden in Adults With Obesity Undergoing Diagnostic Polysomnography for Suspected Obstructive Sleep Apnea: A Prospective Observational Cohort Study

Obesity-related sleep hypoventilation represents a continuum ranging from isolated nocturnal hypoventilation to obesity hypoventilation syndrome. Current diagnostic criteria rely mainly on dichotomous thresholds and may not adequately reflect cumulative nocturnal carbon dioxide exposure.

Hypercapnic burden, defined as the cumulative area under the transcutaneous carbon dioxide (PtcCO₂) curve above a predefined threshold, has recently emerged as a novel physiological marker integrating both the intensity and duration of nocturnal hypercapnia.

Read more

This prospective observational cohort study aims to evaluate the association between nocturnal hypercapnic burden and obstructive sleep apnea severity, assessed by the apnea-hypopnea index (AHI), in adults with obesity referred for diagnostic polysomnography.

Secondary objectives include evaluating associations between hypercapnic burden and sleep architecture, respiratory events, oxygenation parameters, daytime symptoms, and patient-reported outcomes. In addition, the study will investigate the relationship between nocturnal hypercapnic burden and sleep inertia, assessed using the Sleep Inertia Questionnaire (SIQ), based on the hypothesis that greater nocturnal carbon dioxide exposure immediately before awakening may contribute to impaired alertness upon awakening.

Hypothesis: Increased nocturnal hypercapnic burden is associated with greater obstructive sleep apnea severity and reflects an additional physiological dimension of obesity-related sleep hypoventilation beyond conventional polysomnographic indices. Furthermore, higher nocturnal hypercapnic burden is hypothesized to be associated with greater sleep inertia.

Being tested
Sleep Inertia Questionnaire (SIQ)
Keywords
Hypercapnic burden, Transcutaneous carbon dioxide, Polysomnography, Obesity, Sleep apnea, Sleep hypoventilation
Medical subject headings
Sleep Apnea, Obstructive, Obesity, Obesity Hypoventilation Syndrome, Sleep Apnea Syndromes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sleep Inertia Questionnaire (SIQ)Behavioural

    The only research-specific procedure is the completion of the Sleep Inertia Questionnaire (SIQ), a self-administered questionnaire requiring approximately 5 minutes to complete and performed once after the diagnostic sleep study.

Study groups in NCT07809061
Study groupRoleWhat they receive
Adults with obesity referred for diagnostic polysomnographyExperimentalAdults with obesity (body mass index ≥30 kg/m²) referred to the Sleep Medicine Center for routine diagnostic polysomnography because of suspected obstructive sleep apnea
Receives: Behavioral: Sleep Inertia Questionnaire (SIQ)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between nocturnal hypercapnic burden and apnea-hypopnea index

    Correlation between nocturnal hypercapnic burden above 45 mmHg (HB45), defined as the area under the nocturnal transcutaneous carbon dioxide pressure (PtcCO₂) curve above 45 mmHg and normalized per hour of recording (mmHg·min/hour), and the apnea-hypopnea index derived from diagnostic polysomnography (events/hour).

    The correlation will be assessed using Pearson's or Spearman's correlation coefficient, according to data distribution.

    Measured: Baseline only (overnight diagnostic polysomnography)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion3 Nov 2028 (estimated)
  4. Study completion3 Nov 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
Single-centre, prospective, RIPH 3 - research involving human subjects outside of health products
Masking
None (open label)
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07809061
Sponsor's protocol ID
69HCL26_0743
Other IDs
ID RCB
Acronym
HBO-POSA
Status last verified
Aug 2026
First submitted
11 Aug 2026
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Sleep Inertia Questionnaire (SIQ) in people with Obstructive Sleep Apnea and Obesity (BMI>30), run by Hospices Civils de Lyon at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Pierre TANKERE, Dr (0472071929, Pierre.tankere01@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between nocturnal hypercapnic burden and apnea-hypopnea index (time frame: Baseline only (overnight diagnostic polysomnography)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
HBO-POSA Clinical Trial NCT07809061 | AzTrials